Details for New Drug Application (NDA): 090198
✉ Email this page to a colleague
The generic ingredient in LAMIVUDINE is lamivudine; nevirapine; zidovudine. There are twenty-nine drug master file entries for this compound. Additional details are available on the lamivudine; nevirapine; zidovudine profile page.
Summary for 090198
| Tradename: | LAMIVUDINE |
| Applicant: | Macleods Pharms Ltd |
| Ingredient: | lamivudine |
| Patents: | 0 |
Pharmacology for NDA: 090198
| Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Medical Subject Heading (MeSH) Categories for 090198
Suppliers and Packaging for NDA: 090198
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LAMIVUDINE | lamivudine | TABLET;ORAL | 090198 | ANDA | Macleods Pharmaceuticals Limited | 33342-001 | 33342-001-09 | 60 TABLET, FILM COATED in 1 BOTTLE (33342-001-09) |
| LAMIVUDINE | lamivudine | TABLET;ORAL | 090198 | ANDA | Macleods Pharmaceuticals Limited | 33342-002 | 33342-002-07 | 30 TABLET, FILM COATED in 1 BOTTLE (33342-002-07) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
| Approval Date: | May 1, 2019 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 300MG | ||||
| Approval Date: | May 1, 2019 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
